Table 2.
(A) | ||
---|---|---|
Pathway | −log (BH p value) |
Gene names |
GABA receptor signaling | 1.53 | ADCY9, MRAS, GABBR1, ADCY10, KCNH2 |
Gs signaling | 1.53 | ADCY9, VIPR2, GLP1R, MRAS, ADD1, ADCY10 |
ERK/MAPK signaling | 1.37 | YWHAG, ATF1, PPP2R5D, HIST1H3C, MRAS, RAC1, PIK3R5 |
Breast cancer regulation by stathmin 1 | 1.37 | ADCY9, PPP2R5D, MRAS, RAC1, PIK3R5, ADCY10, TUBB |
Superpathway of inositol phosphate compounds | 1.37 | SOCS3, ATP1A1, PPP2R5D, PIK3R5, MTMR7, INPP5A, SIRPA |
IGF-1 signaling | 1.37 | SOCS3, YWHAG, NOV, MRAS, PIK3R5 |
CDK5 signaling | 1.37 | ADCY9, PPP2R5D, NGFR, MRAS, ADCY10 |
Gap junction signaling | 1.36 | ADCY9, NOV, MRAS, PIK3R5, ADCY10, TUBB |
3-phosphoinositide biosynthesis | 1.36 | SOCS3, ATP1A1, PPP2R5D, PIK3R5, MTMR7, SIRPA |
Renin-angiotensin signaling | 1.34 | ADCY9, MRAS, RAC1, PIK3R5, ADCY10 |
(B) | ||
---|---|---|
Pathway | −log (BH p value) |
Gene names |
GABA receptor signaling | 2.49 | ADCY9, ADCY10, KCNH2 |
Phospholipase C signaling | 2.40 | ADCY9, HDAC4, FCGR2A, ADCY10, PLD1 |
Fc receptor-mediated phagocytosis in macrophages and monocytes | 2.09 | DOCK1, FCGR2A, PLD1 |
Gs signaling | 1.79 | ADCY9, ADORA3, ADCY10 |
Serotonin receptor signaling | 1.79 | ADCY9, ADCY10 |
Cellular effects of sildenafil (Viagra) | 1.71 | ADCY9, ADCY10, KCNH2 |
G-protein coupled receptor signaling | 1.57 | ADCY9, ADORA3, ADCY10, ADRA1B |
CXCR4 signaling | 1.53 | DOCK1, ADCY9, ADCY10 |
Gap junction signaling | 1.50 | ADCY9, NOV, ADCY10 |
GPCR-mediated integration of enteroendocrine signaling exemplified by an L cell | 1.41 | ADCY9, ADCY10 |
Endothelin-1 signaling | 1.39 | ADCY9, ADCY10, PLD1 |
Leptin signaling in obesity | 1.37 | ADCY9, ADCY10 |
Role of NFAT in cardiac hypertrophy | 1.35 | ADCY9, HDAC4, ADCY10 |
Dopamine receptor signaling | 1.33 | ADCY9, ADCY10 |
ERK/MAPK signaling | 1.30 | DOCK1, ELF2, YWHAG |
The minus log of the Benjamini-Hochberg (BH) corrected p value is given (values >1.3 indicate significance at adjusted P<0.05).